Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $3.75

Century Therapeutics, Inc. (NASDAQ:IPSC) has received an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $3.75.

Several equities analysts have recently weighed in on the company. Wall Street Zen lowered Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Century Therapeutics in a research note on Saturday, September 27th.

Century Therapeutics Trading Up 3.2%

Shares of NASDAQ:IPSC opened at $0.51 on Friday. The firm has a market cap of $44.34 million, a price-to-earnings ratio of -1.77 and a beta of 1.78. Century Therapeutics has a 12-month low of $0.34 and a 12-month high of $1.83. The stock’s 50-day moving average price is $0.52 and its two-hundred day moving average price is $0.54.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). Century Therapeutics had a negative return on equity of 11.53% and a negative net margin of 19.10%. As a group, research analysts forecast that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Century Therapeutics

Several hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in shares of Century Therapeutics during the 2nd quarter valued at about $248,000. Acadian Asset Management LLC raised its holdings in shares of Century Therapeutics by 101.2% during the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after buying an additional 142,953 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Century Therapeutics by 26.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after buying an additional 38,052 shares during the period. Squarepoint Ops LLC raised its holdings in shares of Century Therapeutics by 56.0% during the 4th quarter. Squarepoint Ops LLC now owns 164,871 shares of the company’s stock valued at $167,000 after buying an additional 59,174 shares during the period. Finally, Nuveen LLC purchased a new stake in shares of Century Therapeutics during the 1st quarter valued at about $75,000. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.